Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent

被引:0
作者
Jonatas Rafael de Oliveira
Samira Esteves Afonso Camargo
Luciane Dias de Oliveira
机构
[1] Universidade Estadual Paulista (UNESP),Departamento de Biociências e Diagnóstico Bucal, Instituto de Ciência e Tecnologia
[2] University of Florida,Department of Restorative Dental Sciences
[3] College of Dentistry,undefined
来源
Journal of Biomedical Science | / 26卷
关键词
L.; Rosemary; Biological activities; Phytotherapy; Therapeutic effects; Prophylactic effects;
D O I
暂无
中图分类号
学科分类号
摘要
Rosmarinus officinalis L. (rosemary) is a medicinal plant native to the Mediterranean region and cultivated around the world. Besides the therapeutic purpose, it is commonly used as a condiment and food preservative. R. officinalis L. is constituted by bioactive molecules, the phytocompounds, responsible for implement several pharmacological activities, such as anti-inflammatory, antioxidant, antimicrobial, antiproliferative, antitumor and protective, inhibitory and attenuating activities. Thus, in vivo and in vitro studies were presented in this Review, approaching the therapeutic and prophylactic effects of R. officinalis L. on some physiological disorders caused by biochemical, chemical or biological agents. In this way, methodology, mechanisms, results, and conclusions were described. The main objective of this study was showing that plant products could be equivalent to the available medicines.
引用
收藏
相关论文
共 961 条
[51]  
da Silva MH(2008) extracts Curr Atheroscler Rep 10 386-430
[52]  
Posadas SJ(2016)Oxidative stress and left ventricular remodelling after myocardial infarction Vasc Pharmacol 81 22-949
[53]  
Caz V(2015)Experimental myocardium infarction in rats: analysis of the model Pharmacol Res 101 74-117
[54]  
Largo C(2015)Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a veterans administration cooperative study BMC Cardiovasc Disord 15 95-1966
[55]  
De la Gándara B(2014)Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem Postinfarction research group Ren Fail 36 413-3552
[56]  
Matallanas B(2018)Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-heart failure trial (V-HeFT) study group Hum Exp Toxicol 37 420-171
[57]  
Reglero G(2007)Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group Food Chem 105 940-25
[58]  
Kayashima T(2013)Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in congestive heart failure (PICO) trial J Kerbala Univ 11 109-463
[59]  
Matsubara K(2014)Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators Chem Res Toxicol 27 1958-361
[60]  
Sinkovic A(2002)A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators J Agric Food Chem 50 3549-70